AF Patient Preferences Towards NOAC Versus VKA Treatment: a Patient Preference Study.
Phase of Trial: Phase IV
Latest Information Update: 09 Feb 2018
At a glance
- Drugs Rivaroxaban (Primary) ; Apixaban; Dabigatran etexilate; Edoxaban; Warfarin
- Indications Atrial fibrillation
- Focus Therapeutic Use
- Acronyms PRiSMA-AF
- Sponsors Bayer
- 16 Mar 2017 Status changed from active, no longer recruiting to completed.
- 22 Feb 2017 Planned End Date changed from 1 Jan 2017 to 1 Feb 2017.
- 22 Feb 2017 Status changed from recruiting to active, no longer recruiting.